Final Nyrada Phase I Clinical Trial Cohort to Commence
Highlights:
• Cohort 6 approved to commence, marking the final stage of Nyrada’s Phase I clinical trial of Xolatryp™. • Safety Review Committee for Nyrada’s Phase I clinical trial has cleared progression following review of safety and pharmacokinetic data from Cohort 5. • Cohort 5 received the highest concentration to date via a 3-hour intravenous infusion – the human equivalent dose that showed 42% cardioprotection in a preclinical study. • No safety concerns were identified in Cohort 5, with no dose-limiting toxicities or adverse effects reported. Nyrada Inc (ASX:NYR), a clinical-stage drug discovery and development company focused
NYR Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)